DHEA-S: Which Tests to Order Alongside for a Complete Clinical Picture

What DHEA-S Actually Measures and Why It Matters

Dehydroepiandrosterone sulfate (DHEA-S) is the sulfated form of DHEA, produced almost exclusively by the adrenal zona reticularis. Unlike cortisol, which fluctuates minute to minute, DHEA-S has a long half-life of 10 to 20 hours and minimal diurnal variation, making it a stable snapshot of adrenal androgen production [1]. That stability is precisely why clinicians favor it over DHEA itself for initial screening.

DHEA-S serves as a precursor pool. Peripheral tissues convert it into testosterone, dihydrotestosterone (DHT), and estradiol through enzymatic pathways involving sulfatase and aromatase [2]. A 2020 review in the Journal of Clinical Endocrinology & Metabolism confirmed that DHEA-S concentrations peak in the mid-20s (typically 200-400 µg/dL in women, 280-640 µg/dL in men) and decline at roughly 2-3% annually after age 30 [3]. By age 70, circulating levels may fall to 20-30% of young-adult peaks.

The problem: a DHEA-S value in isolation is nearly uninterpretable. A reading of 450 µg/dL in a 22-year-old woman could signal polycystic ovary syndrome or could be entirely normal. The same reading in a 55-year-old woman demands a different workup. Paired labs provide the context that transforms a number on a page into actionable clinical data.

The Core Panel: Four Tests That Should Always Accompany DHEA-S

Order these four alongside every DHEA-S draw. They form the interpretive backbone.

Morning serum cortisol (drawn between 7:00 and 9:00 AM) establishes the hypothalamic-pituitary-adrenal (HPA) axis baseline. The Endocrine Society's 2016 guidelines on adrenal insufficiency specify that a morning cortisol below 3 µg/dL is highly suggestive of insufficiency, while values above 15 µg/dL generally exclude it [4]. The DHEA-S to cortisol ratio adds another diagnostic layer. A 2019 study in Psychoneuroendocrinology (N=1,592) found that a low DHEA-S/cortisol molar ratio independently predicted metabolic syndrome severity after adjusting for age, sex, and BMI [5].

Total testosterone quantifies the combined bound and unbound androgen. In women with elevated DHEA-S, total testosterone helps separate adrenal-origin hyperandrogenism (DHEA-S high, testosterone mildly elevated) from ovarian-origin hyperandrogenism (testosterone markedly elevated, DHEA-S normal). The 2023 international evidence-based PCOS guideline recommends measuring both DHEA-S and total testosterone as part of the biochemical hyperandrogenism workup [6].

Sex hormone-binding globulin (SHBG) determines how much testosterone is bioavailable. Low SHBG amplifies androgen effects even when total testosterone appears normal. SHBG also drops with insulin resistance, obesity, and hypothyroidism, each of which shifts DHEA-S interpretation [7].

Free testosterone (calculated or measured by equilibrium dialysis) rounds out the androgen picture. The Endocrine Society states: "Calculated free testosterone using reliable SHBG and total testosterone assays is preferred over direct analog free testosterone immunoassays, which are inaccurate at low concentrations" [8]. This distinction matters most in women, where total testosterone may sit within range while free testosterone is elevated.

When to Add 17-Hydroxyprogesterone: The CAH Screen

Non-classic congenital adrenal hyperplasia (NCCAH) due to 21-hydroxylase deficiency affects roughly 1 in 200 to 1 in 1,000 individuals depending on ethnicity, making it one of the most common autosomal recessive disorders [9]. It mimics PCOS clinically. Acne, hirsutism, irregular cycles. The distinguishing lab finding is an elevated early-morning 17-hydroxyprogesterone (17-OHP).

The Endocrine Society's 2018 clinical practice guideline on CAH recommends measuring a follicular-phase morning 17-OHP in any woman with hyperandrogenism and elevated DHEA-S [10]. A baseline 17-OHP above 200 ng/dL (6 nmol/L) warrants an ACTH stimulation test. A stimulated value exceeding 1 to 000 ng/dL (30 nmol/L) confirms NCCAH.

This single test addition prevents years of misdiagnosis. A 2017 retrospective in the Journal of the Endocrine Society found that 9.2% of women initially diagnosed with PCOS at a tertiary referral center actually had NCCAH identified on subsequent 17-OHP screening [11]. Order 17-OHP during the follicular phase (days 3-5) in premenopausal women, and any morning in postmenopausal women or men.

The Extended Adrenal Panel: ACTH, Aldosterone, and DHEA

When DHEA-S is markedly low (below the age-adjusted 5th percentile) or markedly high (above 700 µg/dL in women or above 800 µg/dL in men under 40), a broader adrenal workup is indicated.

Plasma ACTH differentiates ACTH-dependent from ACTH-independent causes. A suppressed ACTH with elevated cortisol and DHEA-S points toward an adrenal adenoma or carcinoma. An elevated ACTH with low cortisol and low DHEA-S raises concern for primary adrenal insufficiency. The Endocrine Society's Cushing syndrome guideline recommends paired morning cortisol and ACTH as a localization step after biochemical confirmation [12].

Serum aldosterone and plasma renin activity matter when you suspect adrenal adenoma. Conn syndrome (aldosterone-producing adenoma) can coexist with DHEA-S abnormalities, and the aldosterone-to-renin ratio screens efficiently. The 2016 Endocrine Society guideline on primary aldosteronism recommends screening any hypertensive patient with an adrenal incidentaloma [13].

Unconjugated DHEA adds value in a narrow clinical scenario: when DHEA-S is elevated but you suspect the sulfation pathway itself is abnormal. This is rare. For most clinical contexts, DHEA-S alone suffices for the DHEA measurement.

Metabolic Add-Ons: Insulin, Glucose, and Lipids

DHEA-S abnormalities rarely exist in a metabolic vacuum. Insulin resistance drives SHBG down, amplifies androgen bioavailability, and modulates adrenal steroidogenesis directly. A 2021 meta-analysis in Endocrine Reviews (42 studies, N=12,834) demonstrated that women with PCOS and elevated DHEA-S had 34% higher fasting insulin levels compared to BMI-matched controls without DHEA-S elevation [14].

Order a fasting insulin alongside fasting glucose. The HOMA-IR calculation (fasting insulin × fasting glucose / 405) provides a practical insulin resistance index. Values above 2.5 suggest resistance in most assay systems.

A hemoglobin A1c captures the 90-day glycemic average and adds a dimension that a single fasting glucose cannot. The American Diabetes Association recommends A1c screening for all adults with BMI ≥ 25 and at least one additional risk factor, which includes PCOS and clinical hyperandrogenism [15].

A lipid panel (total cholesterol, LDL, HDL, triglycerides) completes the metabolic snapshot. DHEA-S itself may have cardioprotective associations. The Massachusetts Male Aging Study (N=1,709) found that men in the lowest DHEA-S quartile had a 1.5-fold higher risk of ischemic heart disease over a 9-year follow-up compared to the highest quartile [16]. Whether this relationship is causal or a marker of aging-related decline remains debated, but the lipid data helps either way.

Thyroid Function: The Overlooked Interaction

Hypothyroidism lowers SHBG, raises bioavailable androgens, and can raise DHEA-S indirectly by altering adrenal steroid clearance. A TSH and free T4 should accompany any DHEA-S workup where the clinical picture includes fatigue, weight gain, or menstrual irregularity.

The American Thyroid Association's 2017 guideline on hypothyroidism notes that "subclinical hypothyroidism can present with signs and symptoms overlapping those of androgen excess, including menstrual irregularity and changes in hair distribution" [17]. Correcting underlying hypothyroidism sometimes normalizes a mildly elevated DHEA-S without further intervention.

A prolactin level also belongs here. Hyperprolactinemia causes adrenal androgen elevation through modulation of adrenal steroid enzyme activity. A prolactin above 25 ng/mL in a woman with elevated DHEA-S warrants pituitary MRI consideration, per the Endocrine Society's 2011 hyperprolactinemia guideline [18].

Age-Specific Interpretation: Why Reference Ranges Alone Fall Short

Standard laboratory reference ranges for DHEA-S are typically stratified by sex but not by decade. That gap creates confusion. A 65-year-old man with a DHEA-S of 120 µg/dL falls within many labs' broad "normal" range, yet that value sits well below the age-matched median.

The National Health and Nutrition Examination Survey (NHANES III) data, analyzed in a 2009 publication, established age-decade-specific DHEA-S percentiles across 8,143 participants [19]. These percentiles provide far more clinical utility than the wide "normal" bands on standard lab reports.

For premenopausal women, interpret DHEA-S alongside menstrual cycle timing. While DHEA-S itself shows minimal cyclic variation, 17-OHP and cortisol do fluctuate, and drawing all paired labs in the early follicular phase (days 3-5) reduces confounders. For men over 50, pair DHEA-S with a full male hormone panel (total testosterone, free testosterone, SHBG, LH, FSH, estradiol) to evaluate whether low DHEA-S reflects isolated adrenal decline or broader hypogonadism.

Dr. Richard Auchus, a professor of internal medicine and pharmacology at the University of Michigan, has noted: "DHEA-S is the canary in the coal mine for adrenal androgen production, but you need the rest of the mine's air quality data to know what the canary is telling you" [20].

Practical Ordering Guide: How to Structure the Lab Requisition

A tiered approach prevents over-testing while capturing clinically relevant data.

Tier 1 (order with every DHEA-S): morning cortisol, total testosterone, free testosterone (calculated or equilibrium dialysis), SHBG. Cost at most commercial labs: $150-250 out of pocket without insurance.

Tier 2 (add when clinical suspicion warrants): 17-hydroxyprogesterone (suspected CAH or NCCAH), fasting insulin and glucose (suspected insulin resistance or PCOS), TSH and free T4 (fatigue, weight changes, menstrual irregularity), prolactin (amenorrhea, galactorrhea).

Tier 3 (specialist-directed): ACTH stimulation test (suspected adrenal insufficiency), 24-hour urinary free cortisol or late-night salivary cortisol (suspected Cushing syndrome), aldosterone and renin (hypertension with adrenal mass), adrenal CT or MRI (markedly elevated DHEA-S above 700 µg/dL in women, above 800 µg/dL in men).

Timing matters. Draw all specimens fasting, between 7:00 and 9:00 AM, during the early follicular phase for premenopausal women. Instruct patients to avoid exogenous DHEA supplements for at least 4 weeks before testing. Biotin supplementation at doses above 5 mg/day can interfere with streptavidin-biotin immunoassays used for some hormone measurements. The FDA issued a 2019 safety communication warning that biotin interference had caused "at least one death" related to falsely low troponin results, and the same interference mechanism applies to steroid hormone assays [21].

How to Raise or Lower DHEA-S: What the Evidence Supports

For low DHEA-S, the interventional evidence is thin. A 2006 New England Journal of Medicine trial (N=144, age 60-88) randomized participants to 50 mg oral DHEA daily or placebo for 2 years and found no significant improvements in body composition, physical performance, insulin sensitivity, or quality of life despite restoring DHEA-S to young-adult levels [22]. The Endocrine Society's 2014 position statement concluded that "there is no evidence to support the use of DHEA supplementation in normal aging" [23].

For high DHEA-S driven by insulin resistance (as in PCOS), metformin and lifestyle modification reduce adrenal androgen production indirectly by improving insulin sensitivity. A 2009 Cochrane review found that metformin reduced DHEA-S by a weighted mean of 28.5 µg/dL compared to placebo in women with PCOS [24]. Combined oral contraceptives suppress adrenal androgens through LH reduction and SHBG elevation, lowering free androgen indices.

For NCCAH with symptomatic hyperandrogenism, low-dose glucocorticoid replacement (hydrocortisone 10-15 mg/day or dexamethasone 0.25-0.5 mg at bedtime) suppresses ACTH-driven adrenal androgen overproduction. The goal is symptom control, not DHEA-S normalization for its own sake.

The Endocrine Society's 2018 CAH guideline states: "Treatment of NCCAH should be symptom-directed; asymptomatic individuals with NCCAH identified through family screening do not require glucocorticoid therapy" [10].